Androgens have been used in the treatment of bone marrow failure syndromes without a clear understanding of their mechanism of action. Blood counts of patients with dyskeratosis congenita or aplastic anemia with mutations in telomerase genes can improve with androgen therapy. Here we observed that exposure in vitro of normal peripheral blood lymphocytes and human bone marrow-derived CD34 ؉ cells to androgens increased telomerase activity, coincident with higher TERT mRNA levels. Cells from patients who were heterozygous for telomerase mutations had low baseline telomerase activity, which was restored to normal levels by exposure to androgens. Estradiol had an effect similar to androgens on TERT gene expression and telomerase enzymatic activity. Tamoxifen abolished the effects of both estradiol and androgens on telomerase function, and letrozole, an aromatase inhibitor, blocked androgen effects on telomerase activity. Conversely, flutamide, an androgen receptor antagonist, did not affect androgen stimulation of telomerase. Down-regulation by siRNA of estrogen receptor-␣ (ER␣), but not ER, inhibited estrogen-stimulated telomerase function. Our results provide a mechanism for androgen therapy in bone marrow failure: androgens appear to regulate telomerase expression and activity mainly by aromatization and through ER␣.
IntroductionTelomere attrition has been associated with the process of normal aging and as etiologic of aneuploid malignancies (in mouse "knockout" models) and of a variety of human diseases (due to mutations in relevant genes). 1 Telomeres consist of T 2 AG 3 repeats and proximate proteins located at the end of chromosomes that serve to prevent recombination, end-to-end fusion, and activation of DNA damage responses. 2 As DNA polymerase is unable to fully duplicate telomeres during cell divisionthe "end replication problem" 3 -telomeres are eroded until reaching critically short lengths, signaling the cell to cease proliferation (cellular senescence) and apoptosis. 2 To maintain telomeres, some highly proliferative cells, including hematopoietic progenitor and stem cells, express telomerase (TERT), a specialized reverse transcriptase capable of adding DNA repeats to the 3Ј end of telomeric leading strand using an RNA molecule (TERC) as a template. Telomerase also is expressed in the majority of malignant cells of many tissues. 4 Abnormal telomere maintenance is a feature of a variety of human diseases. Dyskeratosis congenita, a constitutional type of aplastic anemia, is caused by mutations in genes involved in telomere maintenance (DKC1 is mutated in X-linked dyskeratosis congenita 5,6 ; TERC, TERT, and TINF2 are mutated in autosomal dominant dyskeratosis congenita [7][8][9] ; and TERT, NOP10, and NHP2 are mutated in autosomal recessive dyskeratosis congenita 10,11 ). Mutations in TERT and TERC also are genetic risk factors for acquired aplastic anemia. 12,13 Although most acquired aplastic anemia is the result of an immune process destroying hematopoietic stem and progenitor cells, 14 predisposit...